ADVFN ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Premium IconPremium Help Menu
CAC 40
8 218,24
-0,32%
Dow Jones
50 915,63
-1,25%
DAX
24 759,05
-0,63%
Brent Oil
92,16
-1,97%
Bitcoin
60 841,93
-4,65%
Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. KalVista Pharmaceuticals Inc (KALV) Cours

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc (KALV)

NASDAQ
26,95
0,00
(0,00%)
À la fermeture: 05 Juin 10:00PM
26,96
0,01
( 0,04% )
Après les heures de négociation: 10:05PM

KalVista Pharmaceuticals Inc (KALV) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
26,96
( 0,04% )
Prix Achat
26,96
Prix Vente
26,97
Volume échangé
1 816 480
26,94 Fourchette du Jour 26,97
9,83 Plage de 52 semaines 26,98
Cap du marché
1,435B
Clôture Veille
26,95
Ouverture
26,96
Dernière Transaction
80
@
26.96
Dernière heure de transaction
22:06:01
Volume financier
US$ 48 967 175
VWAP
26,9572
Volume moyen (3 m)
US$ 3 295 702
Actions en circulation
53 240 888
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-10,75
Bénéfice par action (BPA)
-2,51
Chiffre d'affairess (LTM)
114,48M
Bénéfice net (LTM)
-135,94M

À propos de KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The c... KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
www.kalvista.com
Siège social
Framingham, United States
Fondé
-
KalVista Pharmaceuticals Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker KALV. Le dernier cours de clôture d'KalVista Pharmaceuticals était de US$26,95. Au cours de la dernière année, les actions de KalVista Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 9,83 à US$ 26,98.

KalVista Pharmaceuticals compte actuellement 53 240 888 actions en circulation. La capitalisation boursière d'KalVista Pharmaceuticals est de US$1,44 milliard. KalVista Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -10.75.

KALV Dernières nouvelles

Plus de nouvelles

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Edgar (US Regulatory)
01 Juin 2026
KALV (0,00%)

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
Edgar (US Regulatory)
01 Juin 2026
KALV (0,00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
29 Mai 2026
KALV (0,00%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
27 Mai 2026
KALV (0,00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 Mai 2026
KALV (0,00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 Mai 2026
KALV (0,00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 Mai 2026
KALV (0,00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 Mai 2026
KALV (0,00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 Mai 2026
KALV (0,00%)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.170.63456513624526.7926.9826.79254196626.93955306CS
40.220.82273747195226.7426.9826.68337973126.80332778CS
129.4654.057142857117.526.9815.09360219225.35954218CS
2610.4863.592233009716.4826.9814.22222569323.07627286CS
5213.4299.113737075313.5426.989.83177287519.37699034CS
15617170.6827309249.9626.987.2187264316.88814397CS
2600.461.735849056626.530.74.1263058515.95871633CS

KALV - Frequently Asked Questions (FAQ)

What is the current KalVista Pharmaceuticals Inc share price?
The current share price of KalVista Pharmaceuticals Inc is US$ 26,96
How many KalVista Pharmaceuticals Inc shares are in issue?
KalVista Pharmaceuticals Inc has 53 240 888 shares in issue
What is the market cap of KalVista Pharmaceuticals Inc?
The market capitalisation of KalVista Pharmaceuticals Inc is USD 1,44B
What is the 1 year trading range for KalVista Pharmaceuticals Inc share price?
KalVista Pharmaceuticals Inc has traded in the range of US$ 9,83 to US$ 26,98 during the past year
What is the PE ratio of KalVista Pharmaceuticals Inc?
The price to earnings ratio of KalVista Pharmaceuticals Inc is -10,75
What is the cash to sales ratio of KalVista Pharmaceuticals Inc?
The cash to sales ratio of KalVista Pharmaceuticals Inc is 12,53
What is the registered address of KalVista Pharmaceuticals Inc?
The registered address for KalVista Pharmaceuticals Inc is 200 Crossing Boulevard, Framingham, Massachusetts, 01702
What is the KalVista Pharmaceuticals Inc website address?
The website address for KalVista Pharmaceuticals Inc is www.kalvista.com
Which industry sector does KalVista Pharmaceuticals Inc operate in?
KalVista Pharmaceuticals Inc operates in the Biotechnology & Life Sciences sector

KALV Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
KALV
KalVista Pharmaceuticals
ASX
XSY
S&P ASX 300 Shareholder ...
NASDAQ
AVCA
ASX
BDG
Black Dragon Gold
NYSE
PLYM
Plymouth Industrial REIT
ASX
AUE
Aurum Resources
AMEX
FTRB
Federated Hermes Total R...
LSE
YE21
Fut Treasury.44
TG
BOO
Bloomin Brands
NASDAQ
USON
US Oncology
USOTC
RGGLF
Regional REIT (PK)
NASDAQ
IEP
Icahn Enterprises
NASDAQ
PXS
Pyxis Tankers
NASDAQ
ESGE
iShares Inc iShares ESG ...
BIT
DFNS
Vaneck Defense Ucits Etf
USOTC
IONM
Assure (EM)
Delayed Upgrade Clock
ADVFN
France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2026 ADVFN Ltd - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces